Residencia Odontológica Social y Comunitaria

La Residencia Odontológica Social y Comunitaria (ROSyC) perteneciente a la Secretaria de Planificación y Extensión Universitaria de la FOLP, donde cuenta con su centro operativo. Tiene como objetivos principales brindar servicio a la comunidad y centrar la formación del odontólogo residente en el concepto de salud comunitaria. La práctica de dicha residencia esta vinculada a actividades de terreno a corta distancia (barrios periféricos a la ciudad) y larga distancia (otras provincias de la Argentina).Facultad de Odontologí

The Prostate Is Not a Pill and Therefore Has No Capsule

Tumor staging of prostate cancer is a fundamental principle in management and therapy, with a hallmark being tumor growth beyond the organ boundary. Often, this is referred to as “capsule penetration”, suggesting the existence of a true prostatic capsule that would facilitate the determination of tumor penetration. In fact, the prostate does not have a true capsule and, depending on the anatomic area, it blends with the surrounding fibrous, adipose and muscular tissue. This makes it sometimes difficult or impossible to unequivocally identify extraprostatic tumor extension. It is necessary to appreciate this difficulty in order to better understand the significance of extraprostatic tumor extension

Cribriform versus Intraductal: How to Determine the Difference

International audienceSimple Summary Prostate cancer is a common and challenging disease among men, driving researchers to find better ways to understand and manage it. The understanding of two specific types, cribriform and intraductal prostate cancer (IDC-P), has evolved significantly over the years. This review aims to help pathologists differentiate between cribriform prostate cancer and IDC-P, and addresses current recommendations. Recent studies show that including these features in decision-making tools enhances predictions of cancer recurrence, spread, and patient outcomes. Future research should further focus on their pathological and molecular aspects to improve risk stratification, treatment approaches, and patient care.Abstract Over the years, our understanding of cribriform and intraductal prostate cancer (PCa) has evolved significantly, leading to substantial changes in their classification and clinical management. This review discusses the histopathological disparities between intraductal and cribriform PCa from a diagnostic perspective, aiming to aid pathologists in achieving accurate diagnoses. Furthermore, it discusses the ongoing debate surrounding the different recommendations between ISUP and GUPS, which pose challenges for practicing pathologists and complicates consensus among them. Recent studies have shown promising results in integrating these pathological features into clinical decision-making tools, improving predictions of PCa recurrence, cancer spread, and mortality. Future research efforts should focus on further unraveling the biological backgrounds of these entities and their implications for clinical management to ultimately improve PCa patient outcomes

PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers

International audienceBackground Atezolizumab is an inhibitor of programmed death-ligand 1 (PD-L1), used to treat advanced or metastatic bladder cancer, and in trials for non-invasive disease. In order to be eligible for treatment, patients require a PD-L1 immune cell score ≥ 5%, using the Ventana SP142 PD-L1 assay. Many laboratories do not have access to the required Ventana Benchmark Ultra stainer, and it is unclear if the assay performs similarly on other stainers. In this study, we compare SP142 assay results between Ventana Benchmark Ultra and Leica Bond-III stainers. Methods Serial sections of 90 samples of transurethral bladder resections (comprising 51 pTaHG, 8 pTis, 18 pT1, 10 pT2 tumors) were stained using the SP142 PD-L1 antibody on Ventana Benchmark Ultra and Leica Bond-III stainers, manually scored, and compared using accuracy and Cohen's kappa measures. Results Both devices yielded highly concordant PD-L1 immune cell scores (accuracy 0.84, Cohen's κ 0.732). Moreover, we found similar tumor cell (TC) PD-L1 scores using both stainers, and a trend towards greater TC scores in pT2 stage samples (p = 0.05). Conclusion This study is the first to compare the SP142 antibody in bladder cancer on two different stainers. Our results indicate that both Benchmark Ultra and Bond-III stainers yield highly concordant results using the SP142 PD-L1 antibody

The Genetic Complexity of Prostate Cancer

Prostate cancer (PCa) is a major concern in public health, with many genetically distinct subsets. Genomic alterations in PCa are extraordinarily complex, and both germline and somatic mutations are of great importance in the development of this tumor. The aim of this review is to provide an overview of genetic changes that can occur in the development of PCa and their role in potential therapeutic approaches. Various pathways and mechanisms proposed to play major roles in PCa are described in detail to provide an overview of current knowledge

Pathological reporting of cystectomy lymph nodes: a retrospective analysis of experience in Paris

International audiencePurpose: Pathological evaluation of pelvic lymph node (LN) dissection (PLND) is important for management of cystectomy patients. However, challenges such as unclear interobserver variability of LN counting remain. Here, we assess interobserver variability of LN measures and their clinical utility, with a focus on variant histology.Methods: We retrieved radical cystectomy cases with PLND between 2010 and 2016 and reevaluated pathological parameters; number of total and metastatic LN, LN density (LND), length of metastatic LN and metastases, extranodal extension (ENE).Results: We report 96 patients: median age of 71a, 34 cases pN+, 36 cases with any extent of variant histology, median follow-up 10 months. Perivesical LN were only rarely identified, but frequently metastatic (4/9). Variant histology (34 cases) frequently exhibited LN metastasis (53% of pN+ cases). Interobserver variance was poor for total LN (kappa = 0.167), excellent for positive LN (0.85) and pN staging (0.96), and mediocre for LND (0.53). ROC analysis suggests that both LND and the sum of LN metastasis length may predict outcome (AUC 0.83 and 0.75, respectively).Conclusion: Our study confirms the notion of LND as a prognostic measure, but cautions due to strong interobserver variance of LN counts. The sum length of LN metastases could be a measure that is independent of LN counts. We find that microscopically identified perivesical LN merit particular attention. In summary, our study highlights current challenges in pathological reporting of PLND, confirms previous observations and forms a basis for further studies

Additional file 6 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

Additional file 6: Table S4. Signature genes

Additional file 2 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

Additional file 2. Supplementary Figures 1-14

Additional file 5 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

Additional file 5: Table S3. PSA of RCC cell lines

Additional file 4 of A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

Additional file 4: Table S2. Composition of cohort C2